The latest role of nerve‐specific splicing factor PTBP1 in the transdifferentiation of glial cells into neurons
Central nervous system injury diseases can cause the loss of many neurons, and it is difficult to regenerate. The field of regenerative medicine believes that supplementing the missing neurons may be an ideal method for nerve injury repair. Recent studies have found that down‐regulation of polypyrim...
Gespeichert in:
Veröffentlicht in: | Wiley interdisciplinary reviews. RNA 2023-03, Vol.14 (2), p.e1740-n/a |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Central nervous system injury diseases can cause the loss of many neurons, and it is difficult to regenerate. The field of regenerative medicine believes that supplementing the missing neurons may be an ideal method for nerve injury repair. Recent studies have found that down‐regulation of polypyrimidine tract binding protein 1 (PTBP1) expression can make glial cells transdifferentiate into different types of neurons, which is expected to be an alternative therapy to restore neuronal function. This article summarized the research progress on the structure and biological function of the PTBP family, the mutual regulation of PTBP1 and PTBP2, their role in neurogenesis, and the latest research progress in targeting PTBP1 to mediate the transdifferentiation of glial cells into neurons, which may provide some new strategies and new ideas for the future treatment of central nervous system injury and neurodegenerative diseases.
This article is categorized under:
RNA Processing > Splicing Regulation/Alternative Splicing
Down‐regulation of the expression of the nerve‐specific splicing factor PTBP1 can make the glial cells transdifferentiate into mature neurons, may through alleviating the inhibitory effect of miR‐124 on REST, up‐regulation of the expression of PTBP2 and inhibition the transcriptional activators BRN2 and miR‐9. |
---|---|
ISSN: | 1757-7004 1757-7012 |
DOI: | 10.1002/wrna.1740 |